25 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead … immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target
6-K
id78hdr915dlnfa
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
fa5rqn9xoqhmhhkn kjk
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
vfv0r
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
EX-99.1
t575q3oalyxft0 a01o
30 Dec 22
Connect Biopharma Provides Business and Clinical Development Program Update
8:00am
6-K
9f5jp8iqohwlw
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
uw2ekiq
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
1qgwfut36
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
qg3zalpuoej nwmtk765
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.1
erwxz059o5g40pr8r
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
0idzjc8
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
cyxzbry6t13db
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
68br6j45fd
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.2
my01w 7kfqqnros9em
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
424B4
jls9c yqoljp5
19 Mar 21
Prospectus supplement with pricing info
4:49pm